Mohammed Altyb Alshykh Aboshanab1, Mohammed Elmujtba Adam Essa Adam2,10*, Yousra Abdelmoniem Suleiman3,6, Shaima N Elgenaid4, Sherihan Mohammed Elkundi Osman2,5, Mustafa Mohamed Ali Hussein2,10, Sadia Kamal Albadawi Mohamed7, Mutwaly Defealla Yousif Haron2,10, Shiemaa Emad Abdelrahim6, Leena Abdelrahman Mohammed6, Manhal Habeeb Allah Osman6, Saja Hassan Mohamed6, Salma Ismaeel Rahama6, Saneyya Alsir Ali6, Sadiya Aminu Abdullahi6, Suha Abdallah Musa6, Ziryab Imad Taha Mahmoud9,10, Maha Ismail Elfadul Biuo 10, Abdelkareem A. Ahmed8,10,11*
1Faculty of Medicine, Alzaim Alazhari University, Khartoum, Sudan
2Faculty of Medicine, Alfashir University, Alfashir, Sudan
3Department of Clinical Oncology, Radiation and Isotopes Centre, Khartoum, Sudan
4Faculty of Medicine, University of Khartoum, Khartoum, Sudan
5Department of Molecular Medicine, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
6Faculty of Medicine, Omdurman Islamic University, Khartoum, Sudan
7Faculty of Medicine, University of Gezira, Wad Madani, Sudan
8Department of Physiology and Biochemistry, Faculty of Veterinary Science, University of Nyala, Nyala, Sudan
9Department of Internal Medicine and Rheumatology, Faculty of Medicine, University of Bahri, Khartoum, Sudan
10Department of Cancer Research and Awareness, Medical and Cancer Research Institute (MCRI),Nyala, Sudan
11Institute of Molecular Biology, University of Nyala, Nyala Sudan
*Corresponding Author: Mohammed Elmujtba Adam Essa Adam, Medical and Cancer Research Institute (MCRI) and Faculty of Medicine, AlFashir University, AlFashir, Sudan and Abdelkareem Abdallah Ahmed, Department of Physiology and Biochemistry, Faculty of Veterinary Science, University of Nyala and Medical and Cancer Research Institute (MCRI), Nyala, Sudan.
Received: December 27, 2019; Published: February 10, 2020
Background: Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumour mostly associated with various factors such as advanced age, early menstruation and gene association. We aimed to highlight the effectiveness of second-line chemotherapy in the management of ovarian cancer patients in Sudan.
Methods: The data collected from the hospital patients' records for five years period of time, including 62 patients with ovarian cancer who were treated by the second line platinum-resistant chemotherapy.
Results: The peak prevalence of the disease was found in Al-Jazeera state while the least in Al-Gadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially reduction in mass's size. Others had complete disappearing of the mass or continuing of the tumor growth. All patients received a variant number of cycles of chemotherapy 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. In 50% of patients, cancer recurred after 1-2 months, 32.2% after 3-4 months and 17.8% after 5-6 months. The serous adenocarcinoma was found to be the most histological type whereas the least two types observed were clear cell carcinoma and serous papillary adenocarcinoma.
Conclusion: Our findings suggested that, Al-Jazeera state citizens were more vulnerable to resist first-line chemotherapy than others. The Sudanese patients with ovarian cancer may have a better response to Gemzar but further studies are needed to confirm this result.
Keywords: Adenocarcinoma; Gemzar; Ovarian Cancer; Second Line Chemotherapy, Sudanese Patients
Citation: Mohammed Elmujtba Adam Essa Adam., et al. “Response Rates of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017”.Acta Scientific Women's Health 2.3 (2020): 01-08.
Copyright: © 2020 Mohammed Elmujtba Adam Essa Adam., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.